The trial, known as NRG-CC009, was designed around a different question. Across most solid tumors, stereotactic radiosurgery, or SRS, has become the preferred treatment for patients with a limited number of brain metastases. The technique directs high-dose radiation with sub-millimeter precision at individual lesions while shielding surrounding healthy tissue, and randomized trials in other cancers showed better preservation of cognitive function and quality of life compared with irradiating the whole brain. Small cell lung cancer, however, was the stubborn exception. Patients with this disease were largely excluded from those earlier studies, driven by a persistent concern that treating only visible tumors would leave microscopic disease elsewhere in the brain unchecked, allowing new lesions to emerge and, ultimately, shortening lives. Whole brain radiation therapy therefore remained the standard of care.

What makes the new comparison especially rigorous is that the control arm was not the whole brain treatment of decades past. The study used hippocampal-avoidant whole brain radiation therapy, or HA-WBRT, a modern evolution of the technique that deliberately spares the hippocampi, the paired structures deep in the temporal lobes that are central to forming new memories and are also a known reservoir for circulating cancer cells. Patients in this arm also received memantine, a drug that has been shown to help protect cognitive function during and after whole brain irradiation. In other words, the trial tested focused radiosurgery against the best available version of whole brain treatment, not an easy historical target, which makes the survival signal all the more striking.

Between 2021 and 2026, the investigators randomly assigned 151 patients with small cell lung cancer and brain metastases to one of the two strategies. Eligibility criteria were carefully defined: metastases could be no larger than 4 centimeters, and the total tumor volume within the brain could not exceed 30 cubic centimeters. The protocol initially capped enrollment at patients with up to 10 metastases, but the limit was later removed, and although the median number of metastases was two, some participants had more than 20. This breadth matters, because it suggests the findings could apply to a wider range of patients than the narrow, few-lesion populations that often dominate radiosurgery research.

The primary endpoint of the trial was the length of time before a patient experienced cognitive decline on standardized tests of memory and thinking. On that measure, the two approaches performed similarly, with no significant difference between the groups. Lead principal investigator Vinai Gondi, MD, director of radiation oncology at the Northwestern Medicine West Region and Proton Center in Warrenville, Illinois, suggested that the sophistication of the modern whole brain approach may have narrowed the cognitive gap that earlier studies in other cancers had revealed. There was also a practical complication: because patients in the whole brain arm did not live as long, fewer of them were available for cognitive testing at later follow-up visits, which complicated the interpretation of longer-term neurocognitive outcomes.

The survival difference, by contrast, was unmistakable in magnitude, even as the researchers urged caution in interpreting it. After adjustment for patient and disease characteristics, radiosurgery was associated with a 40 percent lower risk of death. Co-principal investigator Chad Rusthoven, MD, a radiation oncologist at the University of Colorado Anschutz School of Medicine in Aurora, Colorado, emphasized that survival was a prespecified secondary endpoint but that the trial was not designed or specifically powered to prove a survival benefit. At a news briefing at the meeting, he noted that baseline prognostic factors were well balanced between the treatment arms, yet unmeasured variables could still play a role, and it is also possible that the two radiation strategies have differential downstream effects on the disease course that influence survival. Further investigation, he said, is needed before assigning a specific cause to the observed difference.

Equally important for clinical decision-making, the safety picture did not favor one approach over the other. There were no significant differences between the groups in death from neurologic causes, and rates of serious treatment-related side effects did not differ significantly between the cohorts. Central nervous system disease progression was numerically lower with whole brain radiation, consistent with its theoretical advantage of treating microscopic disease, but that difference was not statistically significant in analyses that adjusted for baseline patient characteristics. The historical fear that omitting whole brain treatment would allow the brain to be overrun by new tumors, with catastrophic neurological consequences, was not borne out in this randomized comparison.

For Gondi, the results address a fundamental historical anxiety about small cell lung cancer. The improved survival with radiosurgery, he noted, speaks directly to the concern that omitting whole brain radiation might lead to worse outcomes, a worry that has kept the field anchored to whole brain treatment even as every other tumor type moved toward focused therapy. Overall, he said, the findings support stereotactic radiosurgery as a reasonable option for patients with brain metastases from small cell lung cancer. In a disease where survival has historically been measured in months, a median that approaches a year and a half in the radiosurgery arm represents a meaningful shift in the therapeutic landscape.

The implications for practice could be substantial. Charles B. Simone II, MD, FASTRO, chair of ASTRO’s Lung Cancer Resource Panel and a radiation oncologist at the New York Proton Center and Memorial Sloan Kettering Cancer Center, observed that patients with small cell lung cancer have largely been left out of the randomized trials that established radiosurgery as a standard for brain metastases, and that this study begins to close that evidence gap. With randomized data now in hand, he said, clinicians can have much greater confidence that focused treatment is a reasonable option for appropriately selected patients, with the long-term goal of matching each patient to the treatment that best fits their disease and priorities rather than defaulting to one approach based on diagnosis alone.

What comes next will determine how quickly the findings translate into changed guidelines. Because the survival result emerged from a secondary endpoint in a trial powered for cognitive outcomes, confirmation in larger or dedicated studies will be needed before radiosurgery can claim an unambiguous survival advantage. Yet the convergence of evidence is hard to ignore: no cognitive penalty relative to a modern, memory-sparing whole brain regimen, no excess in serious side effects, no significant increase in neurological deaths, and a median survival twice as long. For a cancer that has long been treated as an exception to every advance in brain metastasis care, the message from Boston is that the exception may finally be ending, and that patients with small cell lung cancer and brain metastases can now enter a genuinely individualized conversation about which radiation strategy is right for them.

Subject of Research: Stereotactic radiosurgery versus hippocampal-avoidant whole brain radiation therapy for brain metastases from small cell lung cancer

Article Title: Radiosurgery linked to longer survival for small cell lung cancer with brain metastases

Article References: Radiosurgery linked to longer survival for small cell lung cancer with brain metastases. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: small cell lung cancer, brain metastases, stereotactic radiosurgery, whole brain radiation therapy, hippocampal avoidance, memantine, NRG-CC009, randomized phase 3 trial, ASTRO, radiation oncology, overall survival, neurocognitive function